参考文献/References:
[1] Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002,CA Cancer J Clin,2005,55(2):74-108.
[2] Nowak AK,Chow PK,Findlay M.Systemic therapy for advanced hepatocellular carcinoma:a review.Eur J Cancer,2004,40(10):1474-1484.
[3] Pommier P,Delannes M,LeFloch O,et al.The French preliminary experience of the use of a seed-projector for exclusive iodine 125 prostate brachytheray:feasibility and acute toxicity.Cancer Radiother,2006,10(8):559-564.
[4] 汤屹,刘文励,周剑锋,等.60Coγ射线照射后肿瘤细胞株的细胞周期阻滞变化.中华放射医学与防护杂志,2003,23(6):418-421.
[5] 张占春,贾廷珍,朱应葆.低剂量照射对细胞周期和修复基因表达的影响.实用肿瘤学杂志,2005,19(2):81-84.
[6] 邵文博,宋金龙.125I粒子近距离照射对BEL-7402肝癌细胞增殖和细胞周期的影响.中国医学物理学杂志,2005,22(4):567.
[7] Nakamura H,Yasui Y,Saito N,et al.DMA repair defect in AT cells and their hypersensitivity to low-dose-rate radiation.Radiat Res,2006,165(3):277-282.
[8] Zhou BB,Elledge SJ.The DNA damage response:putting checkpoints in perspective.Nature,2000,408(6811):433-439.
[9] 代金明,林汝仙,王升启.细胞周期调控与细胞抗辐射能力.辐射研究与辐射工艺学报,2005,23(5):262-265.
[10] Wang Y,Ji P,Liu J,et al.Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapy.Mol Cancer,2009,8:8.
[11] Bull EE,Dote H,Brady KJ,et al.Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldana-mycin.Clin Cancer Res,2004,10(23):8077-8084.
[12] 梁克.放射治疗与细胞凋亡//沈瑜,糜福顺.肿瘤放射生物学.北京:中国医药科技出版社,2001:420-425.
[13] 赵泉,罗开元,时德.125I粒子肝肿瘤组织间植入治疗诱导凋亡的研究,中华实验外科杂志,2005,22(1):112.
[14] Granado-Serrano AB,Martin MA,Bravo L,et al.Quercetin induces apoptosis via caspase activation,regulation of Bcl-2,and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line(HepG2).J Nutr,2006,136(11):2715-2721.
[15] Cory S,Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch.Cancer Cell,2005,8(1):5-6.
[16] 邵文博,韩建奎,宋金龙,等125I粒子植入治疗荷人肝癌裸鼠移植瘤的实验研究.中华核医学杂志,2006,26(1):23-25.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]姚晔,戈伟强,周云,等.BP神经网络模型预测肝肿瘤运动趋势可行性研究[J].国际放射医学核医学杂志,2016,40(1):22.[doi:10.3760/cma.j.issn.1673-4114.2016.01.005]
Yao Ye,Ge Weiqiang,Zhou Yun,et al.Feasibility study on liver tumor motion prediction based on back propagation neural network[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):22.[doi:10.3760/cma.j.issn.1673-4114.2016.01.005]
[3]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[4]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[5]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[6]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[7]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]